Please assess the completion status of the following clinical trial:

Trial Title: CORAL XT - Open-label Extension Trial of the CORAL Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed indicating that the participant understands the purpose of and procedures required for the trial and is willing to participate in the trial.~* Participants must be at least 18 years of age at the Enrollment Visit.~* Women of childbearing potential must have a negative pregnancy test at enrollment and must not be lactating at the Enrollment Visit.~* Participants must be willing to use medically acceptable and highly effective methods of birth control.~* Participants who have completed treatment in KF6005/07 and are still in need of around-the-clock pain analgesia with strong opioids.~Exclusion Criteria:~* The participant has a clinically significant disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments.~* Known to or suspected of not being able to comply with the protocol and the use of cebranopadol.~* Participants taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment.~* History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, bradycardia).~* Concurrent participation in another trial (except participation in KF6005/07) or planning to be enrolled in another clinical trial (i.e., administration of experimental treatment in another clinical trial) during the course of this trial, or previous participation in this trial.~* Employees of the sponsor, investigator, or trial site or family members of the employees, sponsor, or investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cebranopadol (Type: EXPERIMENTAL): Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).